Patents by Inventor James D. Marks

James D. Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to Botulinum Neurotoxins
    Publication number: 20260116958
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxin serotype BoNT/G. The antibodies can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment of pathologies associated with botulinum neurotoxin poisoning.
    Type: Application
    Filed: June 21, 2023
    Publication date: April 30, 2026
    Inventors: James D. Marks, Jianlong Lou, Yongfeng Fan
  • Antibodies for botulinum neurotoxins
    Patent number: 12448463
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: October 21, 2025
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • Antibodies for botulinum neurotoxins
    Patent number: 12441813
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: October 14, 2025
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Shude Yan
  • Anti-TNFR2 antibodies and uses thereof
    Patent number: 12435151
    Abstract: Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 7, 2025
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Yu Zhou, James D. Marks, Marco Muda, James Frank Sampson, Eric M. Tam, Ross Bane Fulton
  • Antibodies to Botulinum Neurotoxins
    Publication number: 20250230224
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment of pathologies associated with botulinum neurotoxin poisoning.
    Type: Application
    Filed: April 7, 2023
    Publication date: July 17, 2025
    Inventors: James D. Marks, Jianlong Lou, Yongfeng Fan, Shude Yan, Maria Consuelo Garcia Rodriguez
  • Antibodies that bind integrin ?v?8 and uses thereof
    Patent number: 12195540
    Abstract: Antibodies that bind to ?v?8 are provided.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: January 14, 2025
    Assignee: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Anthony Cormier, Saburo Ito, Jianlong Lou, James D. Marks, Yifan Cheng, Melody G. Campbell, Jody L. Baron
  • NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
    Publication number: 20250011435
    Abstract: New antibodies and methods of use are described.
    Type: Application
    Filed: July 25, 2024
    Publication date: January 9, 2025
    Applicant: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
  • Neutralizing antibodies to the ?v?8 integrin complex for immunotherapy
    Patent number: 12110334
    Abstract: New antibodies and methods of use are described.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: October 8, 2024
    Assignee: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
  • INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU
    Publication number: 20240026027
    Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
    Type: Application
    Filed: January 13, 2023
    Publication date: January 25, 2024
    Applicant: The Regents of the University of California
    Inventors: Bin Liu, James D. Marks
  • NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
    Publication number: 20230331851
    Abstract: New antibodies and methods of use are described.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 19, 2023
    Applicant: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
  • ANTIBODIES TO BOTULINUM NEUROTOXINS
    Publication number: 20230279084
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.
    Type: Application
    Filed: October 14, 2022
    Publication date: September 7, 2023
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Jianbo Dong, Zhengda Sun
  • ANTIBODIES THAT BIND INTEGRIN AVB8 AND USES THEREOF
    Publication number: 20230279119
    Abstract: Antibodies that bind to ?v?8 are provided.
    Type: Application
    Filed: January 11, 2023
    Publication date: September 7, 2023
    Applicant: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Anthony Cormier, Saburo Ito, Jianlong Lou, James D. Marks, Yifan Cheng, Melody G. Campbell, Jody L. Baron
  • Anti-CD83 antibodies and use thereof
    Patent number: 11725054
    Abstract: The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: August 15, 2023
    Assignees: KIRA BIOTECH PTY LIMITED, THE UNIVERSITY OF QUEENSLAND, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Therese Ann Seldon, David John Munster, Derek Nigel John Hart, Martina Louise Jones, Trent Phillip Munro, Stephen Michael Mahler, Yu Zhou, James D. Marks
  • Antibodies that bind integrin AVB8 and uses thereof
    Patent number: 11608378
    Abstract: Antibodies that bind to ???8 are provided.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 21, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stephen L. Nishimura, Anthony Cormier, Saburo Ito, Jianlong Lou, James D. Marks, Yifan Cheng, Melody G. Campbell, Jody L. Baron
  • Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
    Patent number: 11591402
    Abstract: New antibodies and methods of use are described.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 28, 2023
    Assignee: The Regents of the University of California
    Inventors: Stephen L. Nishimura, Jianlong Lou, James D. Marks, Jody L. Baron, Yifan Cheng, Shenping Wu, Anthony Cormier, Naoki Takasaka
  • Antibodies to botulinum neurotoxins
    Patent number: 11505598
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used in methods to specifically bind and, in some embodiments, neutralize, botulinum neurotoxin and are therefore also useful in the treatment.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 22, 2022
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Jianbo Dong, Zhengda Sun
  • ANTI-TNFR2 ANTIBODIES AND USES THEREOF
    Publication number: 20220281990
    Abstract: Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 8, 2022
    Inventors: Yu ZHOU, James D. MARKS, Marco MUDA, James Frank SAMPSON, Eric M. TAM, Ross Bane FULTON
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20220251240
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: February 3, 2022
    Publication date: August 11, 2022
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez, Shude Yan
  • Antibodies for Botulinum Neurotoxins
    Publication number: 20220089784
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 24, 2022
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • Antibodies for botulinum neurotoxins
    Patent number: 11225525
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: January 18, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez